Log In
Print
BCIQ
Print
Print this Print this
 

KRN5500

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionIV formulation of a semi-synthetic derivative of spicamycin
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat chemotherapy-induced peripheral neuropathy; Treat neuropathic pain in cancer patients
Regulatory Designation

U.S. - Fast Track (Treat chemotherapy-induced peripheral neuropathy);
U.S. - Orphan Drug (Treat chemotherapy-induced peripheral neuropathy)

Partner

Dara BioSciences Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today